Jozef J.P. Nauta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jozef J.P. Nauta has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Iris A. de Bruijn
Solvay Pharmaceuticals, Clinical Development Influenza Vaccines, P.O. BOX 900, 1380 DA Weesp, The Netherlands
2 shared publications- Albert D. M. E. Osterhaus
Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands
1 shared publication Walter E.P. Beyer
Department of Virology|Erasmus Medical Centre
1 shared publication
Latest Publications
- 1 August 2009
- Published by Elsevier in Biologicals
- Vol. 37 (4) , 216-221
On the relationship between mean antibody level, seroprotection and clinical protection from influenza
- 1 August 2009
- Published by Elsevier in Biologicals
- Vol. 37 (4) , 216-221
On the relationship between mean antibody level, seroprotection and clinical protection from influenza
- 30 April 2007
- Published by Elsevier in Biologicals
- Vol. 35 (2) , 153
Reply to Letter to the Editor on “Eliminating bias in the estimation of the geometric mean of HI titres” [Biologicals 2006;34(3):183–6]
- 30 April 2007
- Published by Elsevier in Biologicals
- Vol. 35 (2) , 153
Reply to Letter to the Editor on “Eliminating bias in the estimation of the geometric mean of HI titres” [Biologicals 2006;34(3):183–6]
- 1 September 2006
- Published by Elsevier in Biologicals
- Vol. 34 (3) , 183-186
Eliminating bias in the estimation of the geometric mean of HI titres
- 1 September 2006
- Published by Elsevier in Biologicals
- Vol. 34 (3) , 183-186
Eliminating bias in the estimation of the geometric mean of HI titres
- 1 August 2006
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 16 (4) , 443-452
Statistical Analysis of Influenza Vaccine Lot Consistency Studies
This paper presents an integrated statistical approach to the analysis of influenza vaccine lot consistency studies in which three lots are compared. The approach ensures that the overall Type I error rate (i.e., the probability of wrongly concluding that the lots are similar) is controlled. It is argued that the optimum efficacy measure is the geometric mean titer. The approach is demonstrated using data from a randomized, double-blind lot consistency study in which three consecutive production lots of Solvay Pharmaceutical' new, virosomal subunit influenza vaccine Invivac ® were compared.
- 1 August 2006
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 16 (4) , 443-452
Statistical Analysis of Influenza Vaccine Lot Consistency Studies
This paper presents an integrated statistical approach to the analysis of influenza vaccine lot consistency studies in which three lots are compared. The approach ensures that the overall Type I error rate (i.e., the probability of wrongly concluding that the lots are similar) is controlled. It is argued that the optimum efficacy measure is the geometric mean titer. The approach is demonstrated using data from a randomized, double-blind lot consistency study in which three consecutive production lots of Solvay Pharmaceutical' new, virosomal subunit influenza vaccine Invivac ® were compared.